Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen, Princeton Biomeditech, ABI, Ciphergen, Nasdaq, Organon, Shanghai Genomics, Caprion, Berlex, UC Davis, CombiMatrix, Orion Genomics, Univ. of Glasgow, GE Healthcare


Nanogen and Princeton Biomeditech to Develop Heart Failure IVD

Nanogen has signed a manufacturing and distribution agreement with Princeton Biomeditech to develop a point-of-care in vitro diagnostic assay that detects NT-proBNP, a marker of heart failure, Nanogen said last week in documents filed with the US Securities and Exchange Commission.

According to the terms of the agreement, Nanogen will develop reagents that PBM will incorporate into a final product. Nanogen will be responsible for clinical trials necessary for regulatory approval. PBM will develop a reader for the test, half of whose development will be funded by Nanogen, and the company will seek regulatory approval for the device as well.

PBM will have the right to a nonexclusive license or supply agreement for Nanogen reagents for detecting biomarkers related to congestive heart failure, stroke, or traumatic brain injury. PBM will manufacture the test and its reader, and it gains limited distribution rights.

ABI Reports 4-Percent Revenue Growth in Fiscal Q2; RT-PCR Sales Surge as Sequencing Suffers

Applied Biosystems reported a 4-percent increase in total revenue for its second quarter of fiscal 2006, the company said this week.

ABI had total revenues of $481 million for the three months ended Dec. 31, 2005, compared to $463 million for same period one year ago. The company reported solid growth in its RT-PCR and Applied Genomics unit, where revenues grew 10 percent to $147 million. Revenue for its mass spectrometry segment grew 5 percent to $119 million year over year.

The company's DNA-sequencing segment did not fare as well, sliding more than 1 percent to $141 million. ABI said that it expected revenue growth in the real-time PCR/applied genomics and mass spec product categories to continue, and anticipated a further decline in its DNA sequencing segment.

ABI also reported R&D expenses of $45 million for the quarter, a slight decrease from $47 million a year ago, a decrease ABI attributed to a realignment of its R&D investments.

Net income fell to $31 million from $73 million for the same period last year.

ABI said it expects its growth to be in the low to mid single-digits for the remainder of FY 2006.

ABI Shareholders to Pocket Quarterly Dividend

Applera will pay a quarterly dividend of $.0425 per share to Applied Biosystems shareholders, the company said last week.

The dividend is payable on April 3 to stockholders of record as of the close of business on March 1, the company said.

Ciphergen and Nasdaq Resolve Dispute

The "E" appended to Ciphergen's ticker symbol in November is gone, as the company has been informed by Nasdaq National Market officials that it has "evidenced compliance" in listing requirements, Ciphergen said this week.

Nasdaq questioned Ciphergen's July 2005 stock sale to Quest, suggesting that the deal "constituted a change of control which required shareholder approval" because the deal could result in Quest's owning more than 20 percent of the total outstanding shares. Ciphergen replied that Quest would not own more than 19.9 percent of Ciphergen.

Ciphergen declined to comment on the resolution of the dispute.

Organon and Shanghai Genomics Sign Receptor Research Deal

Organon has secured the cooperation of Shanghai Genomics in the company's program to identify selective steroid hormone receptor modulators, Organon said this week.

The research, which represents Organon's second major research project in China, will focus on rheumatoid arthritis, atherosclerosis, and oncology and will last two years, said Organon.

Financial details were not disclosed.

Shanghai Genomics was founded in August 2001. It merged with Tokyo-based Gene Networks International in June 2005.

Caprion Signs Biomarker Discovery Deal with Berlex

Caprion Pharmaceuticals will collaborate with Berlex to identify pharmacodynamic biomarkers in plasma using its CellCarta platform, the company said this week.

Berlex, a US affiliate of Schering AG, will use the markers in pre-clinical therapy development, according to a statement.

Financial details were not released.

UC Davis Joins CombiMatrix's Core Access Program

The University of California, Davis has joined CombiMatrix's CombiCore access program, Combi parent Acacia Research said this week.

Under the non-exclusive agreement, all UC Davis researchers can purchase, through the UC Davis Genome Center, CombiMatrix's CustomArrays and CatalogArrays, including array processing services performed at the UC Davis Genome Center.

Financial details were not disclosed.

This is the second university CombiMatrix has signed on to its CombiCore program, which the company initiated this quarter. Earlier this month it signed an agreement with the University of Colorado.

Orion Genomics, Univ. of Glasgow Pen Biomarker-Discovery Alliance for Cancer

Scientists at Orion Genomics and the University of Glasgow will try to identify epigenetic biomarkers for developing early cancer screening and personalized therapy options, Orion said last week.

Under the agreement, scientists will use Orion's methylation technologies to identify biomarkers that can be used to detect and treat cancers of the lung, breast, and ovaries.

GE Healthcare Q4 Revenues Up 5.4 Percent

General Electric last week reported that revenues for its healthcare segment increased by 5.4 percent for the fourth quarter of 2005, to $4.49 billion from $4.26 billion during the fourth quarter of 2004.

GE reported total earnings of $18.3 billion for 2005, up 12 percent from $16.3 billion in 2004. Earnings per share were $1.72, up 10 percent from 2004.

The company did not disclose its research and development spending for the fourth quarter of 2005.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.